Mesothelioma News Articles & Scientific Studies

The following is a compilation of news articles and scientific studies addressing various aspects of mesothelioma etiology, diagnosis and treatment. Check back often as this page is regularly updated with newly published articles. Follow us on Twitter for daily updates.

Click Here to Read the Most Recent Articles

Browse Mesothelioma Articles by Topic


Recent Articles

Nintedanib Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso Trial 

(Journal of Clinical Oncology, 9/13/2017)

LUME-Meso is a phase II/III randomized, double-blind trial designed to assess efficacy and safety of nintedanib plus chemotherapy as first-line treatment of malignant pleural mesothelioma (MPM). Phase II results are reported

Chimeric Antigen Receptor (CAR) T Cell Therapy for Malignant Pleural Mesothelioma (MPM).

(NCBI. (9/1/2017)

In this review, we provide a summary of CAR T cell preclinical studies and clinical trials for malignant pleural mesothelioma (MPM), a rare, locally invasive pleural cancer with poor prognosis. We list other attractive potential targets for CAR T cell therapy for MPM, and discuss augmentation strategies of CAR T cell therapy with other forms of immunotherapy in this disease.

The role of radical radiotherapy in the management of malignant pleural mesothelioma: A systematic review.

(NCBI, 8/28/17)

The aim of this systematic review is to assess recent advances in radiotherapy planning and delivery, to ascertain how these developments have impacted on the feasibility of delivering photon-based, high-dose radiotherapy with radical intent in MPM.

Clinical staging of malignant pleural mesothelioma: current perspectives

(NCBI, 8/16/2017)

Currently, the most used measurement system for MPM is the modified Response Evaluation Criteria in Solid Tumors (RECIST) method, which is based on unidimensional measurements of tumor thickness perpendicular to the chest wall or mediastinum.

MicroRNA Expression in Malignant Pleural Mesothelioma and Asbestosis: A Pilot Study.

(NCBI, 8/2/2017)

To identify a pattern of miRNAs as possible diagnostic biomarkers for patients with malignant pleural mesothelioma (MPM) and asbestosis (ASB) and as prognostic biomarkers for MPM patients.

Novel insights into mesothelioma biology and implications for therapy

(NCBI, 7/25/17)

From a genomic standpoint, mesothelioma is characterized by a preponderance of tumour suppressor alterations, for which novel therapies are currently in development. Other promising antitumour agents include inhibitors against angiogenesis, mesothelin and immune checkpoints, which are at various phases of clinical trial testing.

Immune checkpoint therapy of mesothelioma: Pre-clinical bases and clinical evidences.

(NCBI, 7/12/2017)

Treatment with immune-checkpoint blocking monoclonal antibody (mAb) is demonstrating a significant efficacy in different tumor types. Here, we discuss the impact of this promising approach in malignant mesothelioma

 Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma

(NCBI, 7/16/2017)

Investigated the effects of the cytotoxic-T-lymphocyte-associated antigen 4 (CTLA-4) monoclonal antibody tremelimumab in patients with previously treated advanced malignant mesotheImmune checkpoint therapy of mesothelioma: Pre-clinical bases and clinical evidences.lioma.

Evaluation of intracavitary administration of curcumin for the treatment of sarcomatoid mesothelioma

(Oncotarget, 4/13/2017)

A rat model of sarcomatoid mesothelioma, mimicking some of the worst clinical conditions encountered, was established to evaluate the therapeutic potential of intracavitary curcumin administration.

Checkpoint Blockade in Lung Cancer and Mesothelioma.

(NCBI. 3/25/17)

In this concise clinical review, an overview of the landmark clinical trials investigating checkpoint blockade in lung cancer and mesothelioma is provided. Since response rates are around 20% in the majority of clinical trials, there is much room for improvement.

The Immune Microenvironment, Genome-wide Copy Number Aberrations, and Survival in Mesothelioma.

(Journal of Thoracic Oncology, 3/22/2017)

Using a large cohort of patients, we investigated PD-L1 expression, immune infiltrates, and genome-wide copy number status and correlated them to clinicopathological features.

The Controlling Nutritional Status Score Is a Significant Independent Predictor of Poor Prognosis in Patients With Malignant Pleural Mesothelioma

(Clinical Lung Cancer, 3.20/17)

The aim of this study was to clarify the clinical significance of the CONUT in patients with MPM.

Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma

( The Lancet Oncology, 3/15/2017)

Assesses the safety and efficacy of pembrolizumab (an anti-programmed cell death receptor 1 [PD-1] antibody) in advanced solid tumours expressing programmed cell death ligand 1 (PD-L1) and report here on the interim analysis of the malignant pleural mesothelioma cohort.
Malignant Mesothelioma Mortality — United States, 1999–2015

(Center for Disease Control, 3/15/17)

For this report, malignant mesothelioma deaths during 1999–2015 were identified from death certificates and included deaths for which International Classification of Diseases (ICD), 10th Revision codes for malignant mesothelioma¶ were listed as either the underlying or contributing cause of death in the multiple cause-of-death mortality data.

Impact of tumour thickness on survival after radical radiation and surgery in malignant pleural mesothelioma.

(European Respiratory Journal, 3/15/17)

Tumor thickness was assessed to determine if this parameter could refine patients’ selection for multimodality therapy in malignant pleural mesotheliom

Switching off malignant mesothelioma: exploiting the hypoxic microenvironment

(NCBI, 2/16/17)

The relative unspecific symptoms of mesotheliomas, misdiagnoses, and lack of precise targeted therapies call for a more critical assessment of this disease

ComparisImpact of tumour thickness on survival after radical radiation and surgery in malignant pleural mesothelioma.on of outcomes following a cytological or histological diagnosis of malignant mesothelioma

(NCBI, 2/15/17)

Survival with the epithelioid subtype of malignant mesothelioma (MM) is longer than the biphasic or sarcomatoid subtypes. There is concern that cytology-diagnosed epithelioid MM may underdiagnose the biphasic subtype. This study examines survival differences between patients with epithelioid MM diagnosed by cytology only and other subtypes diagnosed by histology.

Mortality Among Coast Guard Shipyard  Workers,  a Retrospective Cohort Study of Specific Exposure

(NCBI, 2/8/17)

In a previous analysis of a cohort of shipyard workers, we found excess mortality from all causes, lung cancer, and mesothelioma for longer work durations and in specific occupations. Here, we expand the previous analyses by evaluating mortality associated with five chemical exposures: asbestos, solvents, lead, oils/greases, and wood dust.

Geographic and socioeconomic factors in patients with malignant pleural mesothelioma in New South Wales and their impact upon clinical outcomes

(Pub Med 2/1/2017)

This study provides evidence for differences in the treatment and survival according to socioeconomic status for compensated MPM patients in NSW.

Asbestos Fibers Detected by Scanning Electric Microscopy in the Gallbladder of Patients with Malignant Pleural Mesothelioma 

(Journal of Microscopy, 1/17)

Gallbladders from patients affected by both malignant pleural mesothelioma (MPM) and important gallbladder disorders were analyzed to verify the presence of asbestos fibres.

Immune Checkpoints Aberrations and Malignant Mesothelioma : Assessment of Prognostic Value & Evaluation of Theraputic Potential 

(NCBI, 1/17)

Role of Post Operative Radiotherapy in the Management of Malignant Pleural Mesothelioma

(NCBI, 1/17)

This study assessed the prognostic impact of postoperative radiotherapy in patients with surgically resected malignant pleural mesothelioma

Successful desensitization of pemetrexed-induced anaphylaxis in a patient with malignant mesothelioma.

(NCBI, 11/16)

The Use of Electron Microscopy For the Diagnosis of Malignant Pleural Mesothelioma 

(Journal of Thoracic Oncology, Vol 11, 10/16)

Transmission electron microscopy (TEM) gave a great impulse to medical research. After its introduction for biological studies in 1931, several microscopic details from observation of animal and tumor cells by TEM were published starting from 1953.

Modulating Immunosuppression in the Intrapleural Space of Malignant Pleural Mesothelioma and Predictive Biomarkers to Guide Treatment Decisions

(Journal of Thoracic Oncology, Vol 11 No. 10/16)

Biphasic Malignant Pleural Mesothelioma Masquerading as a Primary Skeletal Tumor 

(NCBI, 10/16)

Biphasic malignant pleural mesothelioma is a rare malignant tumor, usually presenting as a pleural-based mass in a patient with history of chronic asbestos exposure

Immunotherapy for Malignant Mesothelioma , Reality Check

(NCBI, 10/2016)

Although initial studies have demonstrated proof of principle that manipulating the immune checkpoint axis holds promise in MM, results of some recent large studies using checkpoint inhibitors have been disappointing. Authors believe that in order to demonstrate durable survival benefits, they will need to be used in combination approaches with other immunotherapies, vaccines or chemotherapy.

How Does the Timing of Chemotherapy Affect Outcome Following Radical Surgery for Malignant Pleural Mesothelioma?

(NCBI 10/2016)

Authors aimed to determine whether, in those patients fit for chemotherapy, a delay in this treatment affected survival.

Asbestos Exposure and Histological Subtype of Malignant Mesothelioma 

(NCBI 8/19/16)

It is well recognized that survival time varies with the histological subtype of MM. It is not known, however, if asbestos exposure characteristics (type of asbestos, degree of exposure) are associated with different histological subtypes.

Current Treatment of Mesothelioma: Extrapleural Pneumonectomy Versus Pleurectomy Decortication 

(NCBI 8/15/16)

Although EPP is still performed in highly selected cases, the authors advocate radical P/D whenever possible for patients with MPM.

Impact of Age on Long-Term Outcomes of Surgery for Malignant Pleural Mesothelioma

(NCBI, 5/30/16)

Surgical treatment is associated with improved survival compared with nonoperative management for both patients younger than 70 years and patients aged 70 years or older.

Fatal pleural mesothelioma in Japan (2003-2008): evaluation of computed tomography findings.

(NCBI, 3/29/2016)

The purpose of this study was to clarify the characteristic findings of mesothelioma at the time of diagnosis, and determine precautions and guidelines for diagnosing mesothelioma early in imaging studies

Mesothelioma Gene-Targeting Drug Looks Hopeful

(Medical News Today, 3/15/2016)

A new study raises hope for the treatment of mesothelioma.  It shows that a drug, HRX9 stops tumor growth in mice injected with malignant pleural mesothelioma.

Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations

(NCBI) 2/29/16)

Through integrated analyses, alterations were identified  in Hippo, mTOR, histone methylation, RNA helicase and p53 signaling pathways in MPMs. Read More

Mesothelioma patient derived tumor xenografts with defined BAP1 mutations that mimic the molecular characteristics of human malignant mesothelioma

(NCBI, 2/2/16)

The development and evaluation of new therapeutic approaches for malignant mesothelioma has been sparse due, in part, to lack of suitable tumor models. Read More

Diffuse Pleural Myleoid Sarcoma Mimicking Malignant Mesothelioma

(NCBI, 1/4/16)

Myleoid Sarcoma found with  diffuse pleural involvement mimics malignant pleural mesothelioma.

Pleurectomy Decortication for Mesothelioma- The Procedure of Choice When Possible

(NCBI, 12/9/15)

PD for mesothelioma is associated with greater lung preservation, lower morbidity and mortality, and similar or better survival to EPP. Read More

The Mesothelioma Surgery Shift

(NCBI, 12/9/15)

According to the available data and the recent results of the Batirel study, risk-benefit favors PD rather than EPP for mesothelioma. Read More

An Autopsy Case Report of Malignant Pleural Mesothelioma with Deciduoid Features 

(NCBI, 11.17.15)

Deciduoid mesothelioma is a rare variant of epithelioid mesothelioma. We experienced the case of a 73-year-old man with asbestos exposure who was diagnosed with malignant pleural mesothelioma with deciduoid features. Read More

Asbestos map of Turkey (environmental exposure to asbestos-lung cancer-mesothelioma)

(NCBI, 11/3/15)

Longstanding Asbestos Exposure in Turkey Puts Many at Risk for Mesothelioma . Read More

Pemetrexed-Induced Rash May Be Prevented by Supplementary Corticosteroids.

(NCBI, 11/3/15)

Pemetrexed, a chemotherapeutic drug, is highly active in non-small cell lung cancer and malignant pleural mesothelioma. Read More

Who Let the PET’s Out ?–Who?? Who??

(NCBI, 9/15/15)

Are preoperative position emission tomography/computed tomography and brain magnetic resonance imaging useful or necessary? Read More

New treatment can stop tumours from asbestos in up to 3 out of 4 cases
(Science Alert, 08/13/15)
A new treatment developed by scientists have been shown to arrest the development of mesothelioma tumours, the cancer caused by asbestos exposure, in 60–80 percent of cases. Read More.

Asbestos warning for children: Cancer causing substance found in U.S. crayons and toys imported from China
(Daily Mail, 07/09/15)
Children’s crayons and toy crime scene kits have been found to contain the cancer causing chemical asbestos. Read More.

Researchers find that aspirin can be effective at fighting mesothelioma
(Consumer Affairs, 07/07/15)
Researchers have found that aspirin has the ability to deter the growth of mesothelioma. Read More.

SU-F-207-06: CT-Based Assessment of Tumor Volume in Malignant Pleural Mesothelioma.
(NCBI, 06/30/15)
While image-based volumetry for mesothelioma may not generally capture physical tumor volume as accurately as one might expect, there exists a set of conditions in which CT-based volume is highly correlated with the physical tumor volume. Read More.

Long progression-free survival by pemetrexed continuation maintenance therapy following cisplatin-based chemotherapy in malignant pleural mesothelioma.
(NCBI, 06/26/15)
We herein describe the case of a 69-year-old man with MPM who underwent five cycles of cisplatin plus pemetrexed and exhibited a partial response.This case suggests that pemetrexed maintenance therapy could thus be useful for treating MPM. Read More.

Predictors of lung cancer among former asbestos-exposed workers.
(NCBI, 06/22/15)
Our findings confirm the strong evidence that the lung cancer risk is associated with asbestos exposure and it increases along with the increasing exposure. Read More.

Asbestos-related cancer treatment breakthrough leaves Australian researchers optimistic
(ABC News Australia, 06/14/15)
Australian researchers are cautiously optimistic after using nanocells to achieve what could be one of the most significant breakthroughs in asbestos-related cancer treatment in a decade. Read More.

Asbestos-related lung cancer and malignant mesothelioma of the pleura: selected current issues.
(NCBI, 06/01/15)
Studies to date show that longer, thinner fibers have a stronger association with lung cancer than shorter, less thin fibers, but the latter nonetheless also show an association with lung cancer and mesothelioma. Read More.

BAP1 (BRCA1-associated protein 1) is a highly specific marker for differentiating mesothelioma from reactive mesothelial proliferations.
(NCBI, 05/29/15)
Finding BAP1 loss in mesothelial cells should prompt to immediately reevaluate the patient; moreover, it might be useful in mapping tumor extent and planning surgical resection. Read More.

Epigenetic downregulation of integrin α7 increases migratory potential and confers poor prognosis in malignant pleural mesothelioma.
(NCBI, 05/26/15)
Our data suggests that ITGA7 is an epigenetically regulated tumour suppressor gene and a prognostic factor in human MPM. Read More.

Treatment patterns and survival analysis in 9014 patients with malignant pleural mesothelioma from Belgium, the Netherlands and England.
(NCBI, 05/22/15)
Elderly patients currently account for more than half of all cases of mesothelioma and less toxic treatment options (ie: immunotherapy) will be required to improve their prospects. Read More.

MicroRNAs in mesothelioma: from tumour suppressors and biomarkers to therapeutic targets
(Journal of Thoracic Disease, 05/12/15)
Emerging evidence suggests that exploring aberrant microRNA expression will not only improve our understanding of the disease, but will also lead to the identification of new molecular biomarkers and therapeutic targets. Read More.

The combination of sorafenib and everolimus shows anti-tumor activity in pre-clinical models of malignant pleural mesothelioma.
(NCBI, 05/08/15)
ERM and mTOR pathways are activated in MPM and ‘druggable’ by a combination of sorafenib and everolimus. Combination therapy is a promising therapeutic strategy against MPM. Read More.

A potential immune therapy for mesothelioma. 
(NCBI, 05/08/15)
Results from the KEYNOTE-028 trial show that pembrolizumab is well tolerated and improves clinical outcomes for patients with malignant pleural mesothelioma.  Read More. 

I-Team: Asbestos threat level varies between gov’t agencies
(8 News Now, 05/08/15)
The I-Team became interested in the issue of naturally occurring asbestos in Southern Nevada because health officials engaged in what looks like a blatant case of scientific censorship.  Read More. 

More Danes Dying from Asbestos Exposure Despite 1980s Ban
(Online Post, 05/08/15)
Almost 30 years after the ban of asbestos in Denmark, more and more Danes are dying of mesothelioma.  Read More. 

Alert: Asbestos-Victims May Face Govt. Repayment Issue
(City Watch, 05/08/15)
In the hardball political world of mesothelioma litigation, the asbestos-related cancer that fuels all those commercials, it’s getting hard to tell if some victims are going to be branded as Medicare “scofflaws” or embraced as important whistle-blowers.  Read More. 

Dallas Mesothelioma Attorney says ‘Hypocritical’ House Bill Potentially Devastating for Asbestos Victims
(ADVFN, 05/07/15)
The Texas House of Representatives will vote Friday on legislation that benefits asbestos manufacturers and penalizes victims who are dying from exposure to asbestos. If the bill passes, victims of mesothelioma and other diseases caused by asbestos will suffer devastating consequences, according to Dallas attorney.  Read More. 

 

Back to top


Mesothelioma in the News

Here’s a Look at Keytruda, the Drug that Jimmy Carter Says Made His Tumors Vanish

(NBC  News 12/7/2015)

Jimmy Carter is declared cancer free after using Keytruda, a cancer drug that empowers the immune system. Read More

Schools Fail to Keep Track of Asbestos

(Boston Globe, 12/6/15)

Schools in Massachusetts are Failing to Keep Track of Asbestos claim state and federal officials. Read More

Industry Spins the Revolving Door: Ben Quayle to Lobby on Asbestos Bill He Authored

(Huffington Post, 11/17/15)

Ben Quayle is lobbying for the delay or denial of compensation for sick and dying asbestos victims. legislation he wrote while in Congress.Read More

Asbestos warning for children: Cancer causing substance found in U.S. crayons and toys imported from China
(Daily Mail, 07/09/15)
Children’s crayons and toy crime scene kits have been found to contain the cancer causing chemical asbestos. Read More.

Researchers find that aspirin can be effective at fighting mesothelioma
(Consumer Affairs, 07/07/15)
Researchers have found that aspirin has the ability to deter the growth of mesothelioma. Read More.

Asbestos-related cancer treatment breakthrough leaves Australian researchers optimistic
(ABC News Australia, 06/14/15)
Australian researchers are cautiously optimistic after using nanocells to achieve what could be one of the most significant breakthroughs in asbestos-related cancer treatment in a decade. Read More.

I-Team: Asbestos threat level varies between gov’t agencies
(8 News Now, 05/08/15)
The I-Team became interested in the issue of naturally occurring asbestos in Southern Nevada because health officials engaged in what looks like a blatant case of scientific censorship.  Read More. 

More Danes Dying from Asbestos Exposure Despite 1980s Ban
(Online Post, 05/08/15)
Almost 30 years after the ban of asbestos in Denmark, more and more Danes are dying of mesothelioma.  Read More. 

Alert: Asbestos-Victims May Face Govt. Repayment Issue
(City Watch, 05/08/15)
In the hardball political world of mesothelioma litigation, the asbestos-related cancer that fuels all those commercials, it’s getting hard to tell if some victims are going to be branded as Medicare “scofflaws” or embraced as important whistle-blowers.  Read More. 

Dallas Mesothelioma Attorney says ‘Hypocritical’ House Bill Potentially Devastating for Asbestos Victims
(ADVFN, 05/07/15)
The Texas House of Representatives will vote Friday on legislation that benefits asbestos manufacturers and penalizes victims who are dying from exposure to asbestos. If the bill passes, victims of mesothelioma and other diseases caused by asbestos will suffer devastating consequences, according to Dallas attorney.  Read More. 

Statement by the U.S. Surgeon General Dr. Vivek H. Murthy on National Asbestos Awareness Week 2015
(U.S. Department of Health & Human Services, 04/02/15)
National Asbestos Awareness Week is April 1-7 – a good time to remind Americans about the health dangers of asbestos exposure. Read More.

Taking Aim at Asbestos in Nevada
(New York Times News Service, 02/10/15)
Asbestos occurs naturally in many parts of the country, mostly in the West. But in Nevada, the scientists found, natural erosion and commercial development were sending the fibers into the wind. Read More.

Italian Researchers Predict Impending Global Mesothelioma Crisis
(Asbestos.com, 01/20/15)
Two prominent Italian researchers predict a future international mesothelioma crisis if the widespread use of toxic asbestos continues unabated. Read More.

Global Mesothelioma Epidemic: Trend and Features.
(NCBI, 01/09/15)
Mesothelioma incidence has taken epidemic proportions in various countries. The trend of the epidemic remains undefined. Read More.

Immunotherapy for Malignant Pleural Mesothelioma. Current Status and Future Prospects.

(Global Medical Discovery, 06/23/14)
Pacific Mesothelioma Center use of immunotherapy to treat mesothelioma. Read More.

Promising Treatments for Extending Survival and Improving Quality of Life of Mesothelioma Patients
(The Pacific Mesothelioma Center, 06/17/14)
Groundbreaking research presented at the 4th International Symposium on Lung-Sparing Therapies for Malignant Pleural Mesothelioma. Read More.

Treating Mesothelioma with Immunotherapy
(The Pacific Mesothelioma Center, 05/02/14)
Research update on benefits of using mesenchymal stem cells to treat mesothelioma.‬ Watch the Video.

Device Instantly Reveals if Asbestos Is in Your Air
(Mesothelioma Clinic, 04/29/14)
European researchers are working on a portable airborne ‪asbestos‬ detector.   Read More.

State Ends Asbestos Cleanup by Prisoners
(The News Tribune, 04/21/14)
23 years later Washington shuts down a program that deployed inmates to remove asbestos for $4/hour.   Read More.

Why Insurers Should Fund Medical Research
(BBC News, 04/13/14)
As treatments improve, and more mesothelioma patients live healthy, fulfilling and economically productive lives, the amount of compensation insurers would have to pay out would fall.
Read More.

Disulfiram Suppresses Growth of the Malignant Pleural Mesothelioma Cells in Part by Inducing Apoptosis
(NCBI, 04/09/14)
An FDA-approved drug to treat alcoholism has the potential to treat mesothelioma, as it reduced the growth of tumor cells in mice. Read More.

Strengths, Weaknesses and Opportunities of Diagnostic Breathomics in Pleural Mesothelioma
(NCBI, 04/08/14)
Scientists hope that breath analysis could be the next new method for early detection. Read More. 

Novel Cancer Vaccine Promising Against Ovarian Cancer and Mesothelioma
(Oncology Nurse Advisor, 03/27/14)
A new protein vaccine may provide a new and cost-effective weapon against mesothelioma. Scientists discovered it prolonged survival in animal models of both types of cancer. Read More.

Systematic Stem Cell Therapy Reduces Malignant Mesothelioma Growth
(News Medical, 03/19/14)
Stem cell therapy shows great promise to be the next answer to mesothelioma. Read More.

Occupational and Non-occupational Attributable Risk of Asbestos Exposure for Malignant Pleural Mesothelioma
(NCBI, 02/07/14)
A study suggests that the risk of getting mesothelioma due to the exposure is not lower, even if you don’t work in construction. Read More.

Predictors of Long-Term Survival Following Radical Surgery for Malignant Pleural Mesothelioma
(Oxford Journals, 01/30/14)
Two thoracic surgeons from England came up with a list of factors to predict long-term survival in mesothelioma patients after radical surgery. Read More.

Sealed Air Corp. Finalizes $930M Payment to Asbestos Trusts
(Legal Newsline, 02/10/14)
A bubble wrap manufacturer pays $930 million in cash into two asbestos trusts as part of the bankruptcy settlement agreement. Read More.

Baucus Took ‘Vow’ to Help Libby Residents Harmed by Asbestos
(Missoulian, 02/10/14)
Libby asbestos victims are promised to be covered by Medicare (free hospital care, insured non-hospital care and prescription drugs) regardless of their age. Read More.

Government Report Shines Lights on Asbestos Litigation
(Inside Counsel, 02/06/14)
Companies have set aside more than $30 billion for mesothelioma victims, and approximately 100 companies filed for bankruptcy due to asbestos lawsuits. Read More.

Imaging System Developed for NASA Could Speed-Up Mesothelioma Diagnosis
(Far From Breaking, 02/04/14)
A new kind of technology that creates a unique illuminated microscopic image of cell samples could dramatically improve mesothelioma diagnosis.  Read More.

Gene-Based Mesothelioma Treatment Could Improve Chemotherapy
(Surviving Mesothelioma, 02/04/14)
“Knocking down” mesothelin production with synthetic RNA may offer a novel approach to treating malignant pleural mesothelioma.  Read More.

Systematic Review of the Effects of Asbestos Exposure on the Risk of Cancer Between Children and Adults
(NCBI, 01/30/14)
The study  conducted to investigate whether the first asbestos exposure in childhood increases the risk of asbestos-related cancer including mesothelioma and lung cancer.  Read More.

Mesothelioma Battle for Family
(Stuff, 01/27/14)
Facts and numbers for family mesothelioma battles. Read More.

Landscapes Tainted by Asbestos
(The New York Times Well, 01/17/14)
Naturally occurring asbestos deposits found across the US landscapes. Read More. 

The Children Who Played with Asbestos
(BBC News, 01/12/14)

Children who grew up near an asbestos factory used to play with the leftovers that floated out of the factory. Unfortunately, 50 years later, some of these children and factory workers are now diagnosed with mesothelioma. Read More.

Bakkersland Admits Bread Recall Over Asbestos
(NL Times, 01/09/14)

The largest bakery in the Netherlands admits to recalling shipments of bread because of asbestos. It was recently discovered that many of the old ovens it uses are insulated with asbestos, which possibly contaminated the bread. Read More.

Bid to Impose Cancer Research levy on Insurers is Defeated
(BBC News, 01/07/14)
A bill that would have forced insurance companies to fund mesothelioma research was unable to make it through the British Parliament despite strong support from multiple parties. Read More.

Back to top


Pleurectomy/Decortication (PD) vs. Extra Pleural Pneumonectomy (EPP)

Hemithoracic intensity modulated radiation therapy after pleurectomy/decortication for malignant pleural mesothelioma: toxicity, patterns of failure, and a matched survival analysis.
(NCBI, 01/01/15)
Hemithoracic intensity modulated radiation therapy after pleurectomy/decortication produced little high-grade toxicity but led to progressive declines in pulmonary function; overall survival and progression free survival were better in PD-IMRT compared with EPP-IMRT. Read More.

Is There Life After Mesothelioma and Radical Surgery Trial? Does Extrapleural Pneumonectomy Still Have a Role In the Management of Pleural Mesothelioma? A 13-Year, Single-Center Experience

(NCBI, 02/15/14)

Mesothelioma and radical surgery vs. extrapleural pneumonectomy: the EPP tends to increase survival rates. Read More.

Speak Up: Reflections from a Nightmare Patient – Me!
(Oncology Times, 06/25/10)
Diagnosed in 2007 at the age of 48, Dr. Andrew Lawson is one of three doctors who trained at Guy’s Hospital in London, England diagnosed with mesothleioma. His travels from the diagnosis through his treatment choices are eye-opening. ” I have researched my illness. I see every paper published on Medline on mesothelioma. I have read all the abstracts from the international Mesothelioma Interest Group meetings, and I discussed my treatments with many colleagues from a variety of disciplines. I suppose I am the nightmare patient.” Read More.

Surgical Options in Malignant Pleural Mesothelioma: Extrapleural Pneumonectomy or Pleurectomy/Decortication
(Semin Thorac Cardiovasc Surg, 2009)
Overall survival reported in a recent multi-center analysis of these two operations supports the use of P/D for early stage MPM provided that a complete resection is feasible; otherwise EPP will confer a survival advantage. For stage II disease, however, EPP demonstrates a possible advantage. The focus in stage III disease should remain on the ability to achieve macroscopic complete resection, rather than N2 disease. Patients with stage IV cancers have better survival if the lung is left in place. Read More.

Surgical Techniques for Multimodality Treatment of Malignant Pleural Mesothelioma: Extrapleural Pneumonectomy and Pleurectomy/Decortication
(Semin Thorac Cardiovasc Surg, 2009)
Trimodality treatment of malignant pleural mesothelioma with cytoreductive surgery followed by radiation and chemotherapy has resulted in long-term survival for a select group of patients. Knowledge of the similarities and differences between the two operations that have evolved-extrapleural pneumonectomy and pleurectomy/decortication-is prerequisite to understanding the complex issues associated with patient selection, diagnosis, pathologic staging, preoperative assessment, perioperative management, and adjuvant treatment. Both operations are technically complex and should only be performed at experienced high-volume centers. Read More.

Morbidity, Mortality, Mean Survival, and the Impact of Histology on Survival after Pleurectomy in 64 Patients with Malignant Pleural Mesothelioma
(Int J Surg, 08/08/13)
Our results show that pleurectomy can be performed as a means of palliation for advanced-stage disease with a low mortality rate and may, in fact, improve survival in patients with epithelial subtype as compared with historical controls in the literature with no surgical intervention. Read More.

Extrapleural Pneumonectomy versus Pleurectomy/Decortication in the Surgical Management of Malignant Pleural Mesothelioma: Results in 663 Patients
(European Journal of Cardio-Thoracic Surgery, 03/08/13)
Patients who underwent pleurectomy/decortication had a better survival than those who underwent extrapleural pneumonectomy; however, the reasons are multifactorial and subject to selection bias. At present, the choice of resection should be tailored to the extent of disease, patient comorbidities, and type of multimodality therapy planned. Click Here to Read More or here

Malignant Pleural Mesothelioma: Surgical Management in 285 patients
(Annals of Thoracic Surgery, 01/08/13)
Extrapleural pneumonectomy can be performed with similar 30-day mortality as other procedures for malignant pleural mesothelioma with a median survival better than subtotal pleurectomy, exploration without resection, and biopsy alone. However, extrapleural pneumonectomy has significant morbidity and a 3-year survival of only 14%. Read More.

Extrapleural Pneumonectomy Is the Preferred Surgical Management in the Multimodality Therapy of Pleural Mesothelioma: Con Argument
(The Annals of Surgical Oncology, 07/07/13) Click here

  • No evidence the EPP is superior to lung-sparing P/D
  • Both surgeries carry potentially serious risks
  • Only experienced surgeons should attempt either surgery
  • “The EPP should not become the (Sir Edmund Hillary) operation of Thoracic Surgery: being done simply because it is there and because it can be done

Ten Traps for the Unwary in Surgical Series: A Case Study in Mesothelioma Reports
(The Journal of Thoracic and Cardiovascular Surgery, 06/07/13)
We have to conclude that there is as yet no reliable evidence for the effectiveness of radical surgery or EPP for mesothelioma, and patients should be informed of that fact. Click here

Case-control Study Between Extra-pleural Pneumonectomy and Radical pleurectomy / Decortication for Pathological N2 Malignant Pleural Mesothelioma
(European Journal of Cardio-Thoracic Surgery, 05/07/13)
Preservation of the lung during radical surgery for mesothelioma does not compromise survival even in an older group population. We therefore now have ceased to perform EPP and we make every effort to accurately stage patients with mediastinoscopy to identify them. Read More.

Improved Survival with Interferon Alpha Maintenance Therapy Following Pleurectomy/Decortication and Radiation for Malignant Pleural Mesothelioma
as presented by Dr. Robert Cameron at The Society of Thoracic Surgeon 42nd Annual Meeting (01/06)
Complete pleurectomy/decortication and postoperative radiation therapy may provide similar survival to the more radical procedure of extrapleural pneumonectomy particularly in advanced stage disease. In addition, interferon alpha maintenance therapy may provide substantial improvement in survival over existing therapies. Read More.

Improved Rurvival with VATS Pleurectomy-Decortication in Advanced Malignant Mesothelioma
(Eur J Surg Oncol, 2005)
VATS pleurectomy-decortication is feasible in the majority of cases and independently improves survival for patients with advanced malignant mesothelioma. Read More.

Pleurectomy/Decortication Plus Chemotherapy: Outcomes of 40 Cases of Malignant Pleural Mesothelioma
(ChirItal, 2004)
Low morbidity and mortality and good quality of life after treatment make pleurectomy/decortication with intracavitary and systemic chemotherapy not only a radical approach in early stages, but also a good palliative treatment in advanced malignant pleural mesothelioma, especially in patients who are unsuitable for extrapleural pneumonectomy. Read More.

Back to top


Surgical and Multi-Modal Treatment Options

Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Children, Adolescents, and Young Adults: The First 50 Cases.
(NCBI, 01/07/15)
The best outcome was experienced by patients with desmoplastic small round cell tumor and those with complete cytoreduction. Read More.

“Diffuse” Pleural Mesothelioma.
(The Pacific Mesothelioma Center, 07/22/14)
Implications for surgical technique and adjuvant therapies. Watch the Video.

Promising Treatments for Extending Survival and Improving Quality of Life of Mesothelioma Patients
(The Pacific Mesothelioma Center, 06/17/14)
Groundbreaking research presented at the 4th International Symposium on Lung-Sparing Therapies for Malignant Pleural Mesothelioma. Read More.

Is There Life After Mesothelioma and Radical Surgery Trial? Does Extrapleural Pneumonectomy Still Have a Role In the Management of Pleural Mesothelioma? A 13-Year, Single-Center Experience
(NCBI, 02/15/14)
Mesothelioma and radical surgery vs. extrapleural pneumonectomy: the EPP tends to increase survival rates. Read More.

Predictors of Long-Term Survival Following Radical Surgery for Malignant Pleural Mesothelioma
(Oxford Journals, 01/30/14)
Two thoracic surgeons from England came up with a list of factors to predict long-term survival in mesothelioma patients after radical surgery. Read More.

Extrapleural Pneumonectomy, Photodynamic Therapy and Intensity Modulated Radiation Therapy for the Treatment of Malignant Pleural Mesothelioma
(Cancer Biology and Therapy, 09/10/13)
Intensity modulated radiation therapy (IMRT) has recently been proposed with a multimodality approach for the treatment of mesothelioma, incorporating extrapleural pneumonectomy, intraoperative photodynamic therapy and postoperative hemithoracic IMRT. Multimodality therapy combining surgery with increased doses of radiation using IMRT, and newer treatment modalities such as PDT, appears safe. Future prospective analysis will be needed to demonstrate efficacy of this approach in the treatment of mesothelioma. Read More.

How Successful Is Lung-Preserving Radical Surgery in the Mesothelioma and Radical Surgery-Trial Environment? A Case-Controlled Analysis
(The European Journal of Cardiovasc Surg, 08/10/13) 
Study aims to determine whether there is a survival benefit from open-lung-preserving surgery (radical decortication) for mesothelioma, when compared with the non-radical approach. It concludes that radical open-lung-sparing surgery may confer a survival advantage to patients with mesothelioma, who are fit to undergo radical decortication followed by chemotherapy and radiotherapy. Read More.

Two-Stage Operative Cytoreduction and Intraperitoneal Chemotherapy for Diffuse Malignant Peritoneal Mesothelioma: Operative Morbidity and Mortality in Phase I and II Trials
(European Journal of Surgical Oncology, 07/10/13)
The standard of care for diffuse malignant peritoneal mesothelioma involves operative cytoreduction and intraperitoneal chemotherapy. Most centers favor very aggressive protocol. In our trials, we found that a two-stage cytoreduction with intraperitoneal chemotherapy offers median survival comparable to one-stage protocols, with relatively low morbidity, mortality, visceral resections and length of stay despite two operations. This series supports that our protocol is a feasible and safe approach. Read More.

Phase II Trial of Trimodality Therapy for Malignant Pleural Mesothelioma (EORTC 08031)
(The European Respiratory Journal, 06/10/13)
EORTC 08031 phase II trial investigated the feasibility of trimodality therapy consisting of induction chemotherapy followed by extrapleural pneumonectomy and postoperative radiotherapy in patients with cT3N1M0 or less malignant pleural mesothelioma. Although feasible, trimodality therapy in patients with mesothelioma was not completed within the strictly defined timelines of this protocol and adjustments are necessary.
Read More.

Surgery for Malignant Pleural Mesothelioma
(Expert Review of Respiratory Medicine, 06/10/13)
The role of surgery for malignant pleural mesothelioma encompasses the need for rapid diagnosis, preoperative staging and surgical resection, and also the need for a greater biological understanding of this rare and aggressive malignancy. Pending the discovery of new drugs, the focus of clinical research over the next 5 years will emphasize refinements in patient selection, pathologic staging, molecular staging and other novel adjuvant therapies. Read More.

Analysis of the Effect of Radiotherapy on Malignant Pleural Mesothelioma When Given on Adjuvant or Palliative Basis
(Chinese Journal of Lung Cancer, 01/10/13)
This retrospective study was designed to evaluate the response and survival of malignant pleural mesothelioma to radiotherapy when delivered with surgery and chemotherapy and when delivered alone or with chemotherapy. Multimodality approach involving surgery, chemotherapy and radiotherapy have been evaluated and proved its superiority in improving survival, especially in stages II. Read More.

Back to top


Chemotherapy

A Case of Advanced Malignant Pleural Mesothelioma Treatment With Chemotherapy and Photodynamic Therapy
(NCBI, 01/29/15)
A 68-year-old male received a single photodynamic therapy treatment and then later took chemotherapy using gemcitabine/cisplatin. The patient showed a survival time of 27 months, which is longer than median survival time in advanced MPM patients. Further research is needed. Read More.

Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Children, Adolescents, and Young Adults: The First 50 Cases.
(NCBI, 01/07/15)
The best outcome was experienced by patients with desmoplastic small round cell tumor and those with complete cytoreduction. Read More.

Gene-Based Mesothelioma Treatment Could Improve Chemotherapy
(Surviving Mesothelioma, 02/04/14)
“Knocking down” mesothelin production with synthetic RNA may offer a novel approach to treating malignant pleural mesothelioma.  Read More.

Vinorelbine in Pemetrexed-Pretreated Patients with MPM
(PubMed, 12/17/13)
In a small study, 59 patients who had shown some progress with pemetrexed-platinum chemotherapy, the standard first-line treatment for mesothelioma, were treated with vinorelbine as a second-line treatment. 42 patients showed improvement. Read More.

The Investigation of Effects of Quercetin and Its Combination with Cisplatin on Malignant Mesothelioma Cells in Vitro
(Journal of Biomedicine & Biotechnology, 05/10/13
This study investigated the antiproliferative effect of Quercetin (QU) and its combination with Cisplatin (CIS) on mesothelioma. Our experiments showed that QU significantly reduced the proliferation of cell lines and altered the cell cycle distribution. Additionally, the combination of QU + CIS was found more effective when compared with individual treatment of agents. Read More.

In Vitro and in Vivo Therapeutic Efficacy of the PPAR-Gamma Agonist Troglitazone in Combination with Cisplatin Against Malignant Pleural Mesothelioma Cell Growth
(Cancer Science, 05/10/ 13)
This study examined the therapeutic efficacy of the PPAR-gamma agonist troglitazone (TGZ) in combination with cisplatin against a human mesothelioma cell line, both in vitro and orthotopically inoculated into severe combined immunodeficient (SCID) mice. Theresults suggest that TGZ in combination with cisplatin may become a novel therapy for mesothelioma. Read More.

Back to top


Immunotherapy

Immunotherapy: Could the Human Body Be Trained to Fight Cancer?

(Live Science, (2/7/17)

A potential immune therapy for mesothelioma. 
(NCBI, 05/08/15)
Results from the KEYNOTE-028 trial show that pembrolizumab is well tolerated and improves clinical outcomes for patients with malignant pleural mesothelioma.  Read More. 

The “Trojan Horse” Approach to Tumor Immunotherapy: Targeting the Tumor Microenvironment .
(NCBI, 07/02/14)
Most anticancer therapies including immunotherapies are given systemically; yet therapies given directly into tumors may be more effective, particularly those that overcome natural suppressive factors in the tumor microenvironment. Read More.

Immunotherapy for Malignant Pleural Mesothelioma. Current Status and Future Prospects.
(Global Medical Discovery, 06/23/14)
Pacific Mesothelioma Center use of immunotherapy to treat mesothelioma. Read More.

Promising Treatments for Extending Survival and Improving Quality of Life of Mesothelioma Patients
(The Pacific Mesothelioma Center, 06/17/14)
Groundbreaking research presented at the 4th International Symposium on Lung-Sparing Therapies for Malignant Pleural Mesothelioma. Read More.

Discovery of Mesothelin and Exploiting It as a Target for Immunotherapy 
(NCBI, 05/16/14)
Immunotherapy‬ triggers tumor regression in patients with advanced ‪mesothelioma‬ and opens up the possibility that such an approach can benefit patients with many common ‪‎cancers‬. Read More.

Immune Therapies for Malignant Mesothelioma
(NCBI, 05/16/14)
Immune therapies is a targeted way to stop mesothelioma cells growth. Read More.

Treating Mesothelioma with Immunotherapy
(The Pacific Mesothelioma Center, 05/02/14)
Research update on benefits of using mesenchymal stem cells to treat mesothelioma.‬ Watch the Video.

Novel Cancer Vaccine Promising Against Ovarian Cancer and Mesothelioma
(Oncology Nurse Advisor, 03/27/14)
A new protein vaccine may provide a new and cost-effective weapon against mesothelioma. Scientists discovered it prolonged survival in animal models of both types of cancer. Read More.

Immunotherapy for Malignant Pleural Mesothelioma: Current Status and Future Prospects
(NCBI, 01/22/14)

A review of the particular immunotherapeutic approaches currently evaluated in MPM patients, as well as how immunotherapy might be rationally combined with conventional tumor cytoreductive therapies for this disease. Read More.

Pharmacological Targeting of p53 Through RITA Is an Effective Antitumoral Strategy for Malignant Pleural Mesothelioma
(Cell Cycle, 12/17/14)
P53 is a gene that is often inactivated when mesothelioma tumors attack the body and allows the tumor cells to proliferate. But researchers have found that when the molecule RITA (Reactivation of p53 and Induction of Tumor cell Apoptosis) is added to cells, p53 reactivates and causes the tumor cells to die on their own, which may lead to a route to treating mesothelioma. Read More.

Major Cancer Regressions in Mesothelioma After Treatment with an Anti-Mesothelin Immunotoxin and Immune Suppression
(Science Translational Medicine, 10/23/13)
Study that discusses how immunotoxins have slowed down and even reversed the growth of mesothelial cells. Even showing improvements in patients that had chemotherapy-resistant tumors. Read More.

Low-Dose Cyclophosphamide Synergizes with Dendritic Cell-Based Immunotherapy in Antitumor Activity
(Journal of Biomedicine and Biotechnology05/10/13)
Mesothelioma tumor-bearing mice were treated with dendritic cell-based immunotherapy alone or in combination with low-dose of cyclophosphamide. The addition of cyclophosphamide improved immunotherapy leading to an increased median and overall survival. Future studies are needed to address the usefulness of this combination treatment for mesothelioma patients. Read More.

Back to top


Diagnosis and Imaging Techniques

SU-F-207-06: CT-Based Assessment of Tumor Volume in Malignant Pleural Mesothelioma.
(NCBI, 06/30/15)
While image-based volumetry for mesothelioma may not generally capture physical tumor volume as accurately as one might expect, there exists a set of conditions in which CT-based volume is highly correlated with the physical tumor volume. Read More.

Potential tools to predict local tumor outgrowth at the intervention site in malignant pleural mesothelioma.
(NCBI, 04/08/15)
We propose that the M2/total TAM ratio and the CD8+ T-cell amount are potential tools to predict which MPM patients are prone to develop LTO.  Read More. 

Detection of malignant mesothelioma using nuclear structure of mesothelial cells in effusion cytology specimens.
(NCBI.gov, 01/16/15)
Nuclear structure of mesothelial cells alone may contain enough information to separate malignant mesothelioma from benign mesothelial proliferations. Read More.

CD157 Important in Malignant Pleural Mesothelioma.
(News Medical, 08/20/14)
CD157 may be useful in the stratification of patients into different prognostic groups. Read More.

Malignant Pleural Mesothelioma : Rationale for a New TNM Classification.
(NCBI, 07/08/14)
An improved staging system will contribute to the design of prospective multi-institutional clinical trials investigating novel treatment strategies for mesothelioma.  Read More. 

Biomarkers Accurately Distinguish Mesothelioma from Non-Cancerous Tissue
(The Today Online, 06/08/14)
After screening 742 miRNAs, the investigators identified miR-126, miR-143, miR-145, and miR-652 as the best candidates to diagnose MPM. Read More.

Device Instantly Reveals if Asbestos Is in Your Air
(Mesothelioma Clinic, 04/29/14)
European researchers are working on a portable airborne ‪asbestos‬ detector.   Read More.

Strengths, Weaknesses and Opportunities of Diagnostic Breathomics in Pleural Mesothelioma
(NCBI, 04/08/14)
Scientists hope that breath analysis could be the next new method for early detection. Read More. 

Retrospective Analysis of Large-Scale Research Screening of Construction Workers for the Early Diagnosis of Mesothelioma
(NCBI, 03/27/14)
Scientists hope a blood tumor marker can detect early stages of mesothelioma. Read More.

CD74: A New Prognostic Factor for Patients with Malignant Pleural Mesothelioma
(NCBI, 03/17/14)
The pro-inflammatory cytokine migration inhibitory factor (MIF) and its receptor CD74 have been proposed as possible therapeutic targets in several cancers. Read More. 

“Dry” Pleural Mesothelioma Successfully Diagnosed on Endobronchial Ultrasound (EBUS)-Guided Transbronchial Needle Aspiration (TBNA)
(NCBI, 03/06/2014)
First case of successful “dry” malignant pleural mesothelioma diagnosis via ultrasound-guided needle aspiration. Read More.

The Value of Inflammatory Parameters in the Prognosis of Malignant Mesothelioma
(NCBI, 02/26/14)
Do inflammatory parameters increase mesothelioma survival rates? Read More.

Imaging System Developed for NASA Could Speed-Up Mesothelioma Diagnosis
(Far From Breaking, 02/04/14)
A new kind of technology that creates a unique illuminated microscopic image of cell samples could dramatically improve mesothelioma diagnosis.  Read More.

Claudin-4 immunohistochemistry is highly effective in distinguishing adenocarcinoma from malignant mesothelioma in effusion cytology
(Cancer Cytopathology, 1/13/14)
Adenocarcinoma of the lung is the most common type of lung cancer found in non-smokers. However, during diagnosis, it is difficult to distinguish from malignant mesothelioma. Researchers found that when mixed with the protein, Claudin-4, tumor cells with adenocarcinoma can be stained but mesothelioma tumors show no stains, which makes it an effective diagnostic tool. Read More.

Researchers Say Nano-Technology Could Improve Mesothelioma Diagnosis, According to Surviving Mesothelioma
(PR Web, 12/4/13)
Researchers in Germany have used Nanotechnology as an early diagnosis tool for mesothelioma, which can increase the chances of survival. The new technology analyzes microscopic tissue samples using “hyperspectral imaging” and increase accuracy in mesothelioma diagnosis. Read More.

An electronic nose distinguishes exhaled breath of patients with Malignant Pleural Mesothelioma from controls

(Lung Cancer, 8/18/11)
Study that discusses how an “electronic nose” can detect a specific marker in the breath of patients with MPM which allows for an earlier diagnosis. It can even distinguish breaths between patients who have MPM and those who have been exposed to asbestos but do not have the cancer. Read More.

Secretion of intelectin-1 from malignant pleural mesothelioma into pleural effusion
(British Journal of Cancer, 08/10/13)
It is hard to diagnose mesothelioma at the early stage because a sensitive and reliable diagnostic marker for mesothelioma has not been found in plasma or pleural effusion. Study found that pleural effusion of mesothelioma patients contained a higher concentration of intelectin-1 than that of lung cancer patients. These results suggest that detection of intelectin-1 may be useful for a differential diagnosis of epithelioid-type mesothelioma in immunohistochemistry and that a high concentration of intelectin-1 in pleural effusion can be used as a new marker for clinical diagnosis of mesothelioma. Read More.

Soluble mesothelin-related Peptide and osteopontin as markers of response in malignant mesothelioma
(Journal of Clinical Oncology, 06/10/13)
In mesothelioma, radiologic assessment of disease status is difficult. Both soluble mesothelin-related peptide (SMRP) and osteopontin (OP) have utility in distinguishing mesothelioma from benign pleural disease. Study found that percentage changes in SMRP levels, but not changes in OP levels, are a potentially useful marker of disease course. These findings should be validated prospectively for a role as an objective adjunctive measure of disease course in both clinical trials and clinical practice. Read More.

Imaging in pleural mesothelioma: A review of Imaging Research Presented at the 9th International Meeting of the International Mesothelioma Interest Group
(Lung Cancer, 06/10/13)
Imaging of mesothelioma poses many challenges for imaging specialists and clinicians due to the anatomic location and unique growth pattern of this tumor. The use of fluorodeoxyglucose positron emission tomography (FDG-PET) at the point of diagnosis, in prognostication, and in the assessment of response to chemotherapy showed a high sensitivity and specificity for differentiation of benign from malignant pleural disease when combined with CT scans. Read More.

Integrated positron emission tomography-computed tomography does not accurately stage intrathoracic disease of patients undergoing trimodality therapy for malignant pleural mesothelioma
(The Thoracic and Cardiovascular Surgeon, 06/10/13)
The results of trimodality therapy for mesothelioma are related to staging by various imaging tests, all of which have limitations. Study found that PET-CT does not accurately identify advanced tumor stage (T4) or mediastinal nodal disease (N2). Read More.

Development of an enzyme-linked immunosorbent assay for the detection of human calretinin in plasma and serum of mesothelioma patients
(BMC Cancer, 05/10/13)
Study developed an enzyme-linked immunosorbent assay (ELISA) for human calretinin in blood and to assess its usefulness as a potential minimally invasive diagnostic marker for mesothelioma. Study found novel assay is highly sensitive and applicable to human serum and plasma. Calretinin appears to be a promising marker for the blood-based detection of mesothelioma and might complement other markers. Read More.

9p21 deletion in the diagnosis of malignant mesothelioma, using fluorescence in situ hybridization analysis
(Pathology International, 05/10/13)
9p21 homozygous deletion correlated well with p16 protein expression in the tumor cells. Study suggests that 9p21 homozygous deletion assessed by FISH on paraffin-embedded tissue may be very useful for differentiating mesothelioma from reactive mesothelial proliferation. Read More.

Back to top


New and Innovative Treatments

The combination of sorafenib and everolimus shows anti-tumor activity in pre-clinical models of malignant pleural mesothelioma.
(NCBI, 05/08/15)
ERM and mTOR pathways are activated in MPM and ‘druggable’ by a combination of sorafenib and everolimus. Combination therapy is a promising therapeutic strategy against MPM. Read More.

FDA grants orphan drug designation to tremelimumab for malignant mesothelioma
(Healio HemOncToday, 04/15/15)
The FDA granted orphan drug designation to tremelimumab — an anti-CTLA–4 monoclonal antibody — for the treatment of patients with malignant mesothelioma.  Read More. 

FDA grants orphan drug designation to CRS-207 for mesothelioma
(Healio HemOncToday, 03/27/15)
The FDA granted orphan drug designation to CRS-207 — a novel immuno-oncology product candidate — for the treatment of patients with malignant pleural mesothelioma. Read More.

Is Radiotherapy Useful for Treating Pain in Mesothelioma? A Phase II Trial. 
(NCBI, 02/04/15)
Radiotherapy for pain control in MPM is an effective treatment in a proportion of patients. Read More.

Genetic Mutation Increases Survival Time for Mesothelioma Patients.
(Asbestos.com, 11/25/14)
The genetic mutation that increases the chances of developing mesothelioma now is identified as the same one that leads to a dramatic increase in survival time — creating real hope for future therapeutic advances. Read More.

Vegetable Compound May Enhance Mesothelioma Drug Treatment.
(PR Web, 11/06/14)
Doctors in France are calling the naturally occurring vegetable compound PEITC a “potential new therapeutic strategy” for malignant pleural mesothelioma. Read More.

Curcumin Spice Linked to Slowing of Lung Lining Cancer.
(Business Standard, 10/20/14)
Derivative of the spice turmeric and cancer-inhibiting peptides, increase levels of a protein inhibitor known to combat the progression of mesothelioma. Read More.

“Diffuse” Pleural Mesothelioma.
(The Pacific Mesothelioma Center, 07/22/14)
Implications for surgical technique and adjuvant therapies. Watch the Video.

Promising Treatments for Extending Survival and Improving Quality of Life of Mesothelioma Patients
(The Pacific Mesothelioma Center, 06/17/14)
Groundbreaking research presented at the 4th International Symposium on Lung-Sparing Therapies for Malignant Pleural Mesothelioma. Read More.

Treating Mesothelioma with Immunotherapy
(The Pacific Mesothelioma Center, 05/02/14)
Research update on benefits of using mesenchymal stem cells to treat mesothelioma.‬ Watch the Video.

CD26-Mediated Regulation of Periostin Expression Contributes to Migration and Invasion of Malignant Pleural Mesothelioma Cells
(NCBI, 04/24/14)
Expression of protein CD26 enhances #mesothelioma cells activity.  Read More.

Anetumab Ravtansin – a Novel Mesothelin-Targeting Antibody-Drug Conjugate Cures Tumors with Heterogeneous Target Expression Favored by Bystander Effect
(NCBI, 04/08/14)
Antibody-drug conjugates shows positive results in treating mesothelin types of cancer such as mesothelioma. Read More.

Disulfiram Suppresses Growth of the Malignant Pleural Mesothelioma Cells in Part by Inducing Apoptosis
(NCBI, 04/09/14)
An FDA-approved drug to treat alcoholism has the potential to treat mesothelioma, as it reduced the growth of tumor cells in mice. Read More.
Novel Cancer Vaccine Promising Against Ovarian Cancer and Mesothelioma
(Oncology Nurse Advisor, 03/27/2014)
A new protein vaccine may provide a new and cost-effective weapon against mesothelioma. Scientists discovered it prolonged survival in animal models of both types of cancer. Read More.

Cordotomy in Mesothelioma-Related Pain: Systematic Review
(NCBI, 03/24/14)
Scientists suggest cordotomy can become an effective and safe pain killer for mesothelioma, however, more evidence is still needed to aid decision making on continued provision. Read More.

Systematic Stem Cell Therapy Reduces Malignant Mesothelioma Growth
(News Medical, 03/19/14)
Stem cell therapy shows great promise to be the next answer to mesothelioma. Read More.

Immunotherapy for Malignant Pleural Mesothelioma: Current Status and Future Prospects
(NCBI, 01/22/14)
A review of the particular immunotherapeutic approaches currently evaluated in MPM patients, as well as how immunotherapy might be rationally combined with conventional tumor cytoreductive therapies for this disease. Read More.

Human Stem Cells Used to Create Lung Tissue
(Yahoo! News, 12/3/13)

Human stem cells have been converted into functioning lung cells for the first time, paving the way for better models of lung diseases, ways to test potential drugs and, ultimately, creation of tissue for lung transplants. They’ve even made hamburgers from them! Read More.

‘Ray of hope’ for Sufferers of Asbestos Disease Mesothelioma
(ABC News Australia, 11/30/13)
Researchers in Australia have found that mini cells that carry genetic material can limit the growth of mesothelioma tumors. Read More.

Valproate-doxorubicin: promising therapy for progressing mesothelioma. A phase II study
(The European Respiratory Journal, 06/10/13)
In vitro data suggested that valproic acid (VA), a histone deacetylase inhibitor (HDACi), had pro-apoptotic effect and synergized with doxorubicin (D) to induce apoptosis in mesothelioma cells. Study aims to determine response rate of combined VA and D in patients with unresectable mesothelioma failing after platinum-based CT. Read More.

Back to top


Origin and Case Studies

Network analysis of immunotherapy-induced regressing tumours identifies novel synergistic drug combinations.
(NCBI, 07/21/15)
We hypothesized that the effector response in the tumour could be visualized as a complex network of interacting gene products and that by mapping this network we could predict effective pharmacological interventions. Here, we provide proof of concept for the validity of this approach in a murine mesothelioma model, which displays a dichotomous response to anti-CTLA4 immune checkpoint blockade.. Read More.

Emerging evidence that the ban on asbestos use is reducing the occurrence of pleural mesothelioma in Sweden.
(NCBI, 07/20/15)
The ban and decreased use of asbestos in Sweden can be measured today in birth cohorts that started their working career after the decrease. Read More.

Predictors of lung cancer among former asbestos-exposed workers.
(NCBI, 06/22/15)
Our findings confirm the strong evidence that the lung cancer risk is associated with asbestos exposure and it increases along with the increasing exposure. Read More.

Long progression-free survival by pemetrexed continuation maintenance therapy following cisplatin-based chemotherapy in malignant pleural mesothelioma.
(NCBI, 06/26/15)
We herein describe the case of a 69-year-old man with MPM who underwent five cycles of cisplatin plus pemetrexed and exhibited a partial response.This case suggests that pemetrexed maintenance therapy could thus be useful for treating MPM. Read More.

Treatment patterns and survival analysis in 9014 patients with malignant pleural mesothelioma from Belgium, the Netherlands and England.
(NCBI, 05/22/15)
Elderly patients currently account for more than half of all cases of mesothelioma and less toxic treatment options (ie: immunotherapy) will be required to improve their prospects. Read More.

Asbestos-related lung cancer and malignant mesothelioma of the pleura: selected current issues.
(NCBI, 06/01/15)
Studies to date show that longer, thinner fibers have a stronger association with lung cancer than shorter, less thin fibers, but the latter nonetheless also show an association with lung cancer and mesothelioma. Read More.

BAP1 (BRCA1-associated protein 1) is a highly specific marker for differentiating mesothelioma from reactive mesothelial proliferations.
(NCBI, 05/29/15)
Finding BAP1 loss in mesothelial cells should prompt to immediately reevaluate the patient; moreover, it might be useful in mapping tumor extent and planning surgical resection. Read More.

Epigenetic downregulation of integrin α7 increases migratory potential and confers poor prognosis in malignant pleural mesothelioma.
(NCBI, 05/26/15)
Our data suggests that ITGA7 is an epigenetically regulated tumour suppressor gene and a prognostic factor in human MPM. Read More.

Early Findings with KEYTRUDA® (pembrolizumab), Merck’s Anti-PD-1 Therapy, in Patients with Advanced Pleural Mesothelioma Presented at AACR Annual Meeting
(Business Wire, 04/19/15)
KEYTRUDA demonstrated 28 percent overall response rate and 76 percent disease control rate in difficult-to-treat cancer. First findings from KEYNOTE-028, Merck’s innovative basket trial in 20 cancers.  Read More. 

Interventional therapies for malignant pleural effusions: the present and the future.
(NCBI, 04/15/15)
The approach to management of malignant pleural effusions (MPE) has changed over the past few decades. The key goals of MPE management are to relieve patient symptoms using the least invasive means and in the most cost-effective manner.  Read More. 

Asbestos fibres in the lungs of an american mechanic who drilled, riveted, and ground brake linings: a case report and discussion.
(NCBI, 04/08/15)
The authors reported that ‘the sampling results indicate that the brake mechanics sampled are exposed to extremely high asbestos concentrations , suggesting that this occupational group could be at excess risk of asbestos-related diseases’. Read More.

Tumoral CD10 Expression Correlates with Aggressive Histology and Prognosis in Patients with Malignant Pleural Mesothelioma.
(NCBI.gov, 01/22/15)
Tumoral CD10 expression correlated with aggressive histologic types and higher mitotic activity and is an independent prognostic factor for patients with malignant pleural mesothelioma. Read More.

Italian Researchers Predict Impending Global Mesothelioma Crisis
(Asbestos.com, 01/20/15)
Two prominent Italian researchers predict a future international mesothelioma crisis if the widespread use of toxic asbestos continues unabated. Read More.

Global Mesothelioma Epidemic: Trend and Features.
(NCBI, 01/09/15)
Mesothelioma incidence has taken epidemic proportions in various countries. The trend of the epidemic remains undefined. Read More.

British Asbestos Expert Says Fluffy Is an International Worst Nightmare
(The Canberra Times, 11/14/14)
After two decades researching, publishing and lobbying on the need for asbestos eradication, British historian and asbestos campaigner Laurie Kazan-Allen talks about Mr Fluffy. Read More.

Tracking Asbestos Exposure Occurrences.
(Associated Press, 10/25/14)
Penn State started a new study on asbestos exposure. Read More.

Asbestos in Commercial Cosmetic Talcum Powder as a Cause for Mesothelioma in Women.
(NCBl, 10/20/14)
Digestions of the tissues were found to contain anthophyllite and tremolite asbestos. Read More.

Characterization and drug sensitivity profiling of primary malignant mesothelioma cells from pleural effusions.
(NCBI, 09/24/14)
The proportion of malignant cells and RRM1 reactivity in the pleural effusions correlate to drug sensitivity and survival time. The variability in response to the commonly used chemotherapies emphasizes the need for tests that indicate best individual choice of cytotoxic drugs. Read More.

Increased levels of C-C chemokine RANTES in asbestos exposed workers and in malignant mesothelioma patients from an hyperendemic area.
(NCBl, 08/27/14)
This study shows that, in subjects from an hyperendemic area for MM, the C-C chemokine RANTES is associated with the exposure to asbestos fibres. If validated in larger samples, this factor could have the potential to be a critical biomarker for MM prognosis as recently reported for breast tumor. Read More.

Asbestos Case and Its Current Implications on Global Health.
(NCBI, 07/08/14)
Prevention of asbestos-related disease requires international cooperation, transfer of know-how and dissemination of successful procedures in order to contrast asbestos exposure in the frame of a global environmental health approach. Read More.

Women with Malignant Pleural Mesothelioma Have a Threefold Better Survival Rate than Men.
(NCBI, 06/19/14)
Study shows that while malignant pleural ‪‎mesothelioma‬ is less common in women, they still have higher survival rates. Read More.

Is One Single Exposure to Asbestos Life-Threatening?
(NCBI, 05/06/14)
The risk of development of lung cancer was higher for anyone with increased years of exposure to asbestos fibre combined with a smoking habit.‬  Read More.

A Systematic Review of Occupational Exposure to Synthetic Vitreous Fibers and Mesothelioma
(NCBI, 05/05/14)
Exposure to synthetic vitreous fibers at work does not increase the risk of ‪‎mesothelioma‬.  Read More.

Relationship Between Prognosis and Neutrophil: Lymphocyte and Platelet
(NCBI, 04/16/14)
Mesothelioma survival rates appear to depend on the number of white cells a patient has.   Read More.

Multicystic Benign Cystic Mesothelioma Presenting as a Pelvic Mass
(NCBI, 04/08/14) Case Study: Multicystic benign cystic mesothelioma masking as a pelvic mass. Final diagnosis was not available until the time of surgery. Read More. 

The 5 Jobs Most Likely to Make You Sick
(Fox News, 02/23/14)
Construction workers took the second place on the top 5 list of the most risky jobs due to the ‪‬ asbestos exposure. Read More.

Corrette Power Plant Shuts Down After Asbestos Leak
(Ravalli Republic, 02/20/14)
Montana power plant shuts down after a steam tube failed on a boiler and damaged insulation containing asbestos. Workers have been sent home. Read More.

Asbestos Toxins Made DIY Risky

(The Press, 02/18/14)
An increase in asbestos-related diseases among do-it-yourself home renovators. Read More.

Occupational and Non-occupational Attributable Risk of Asbestos Exposure for Malignant Pleural Mesothelioma
(NCBI, 02/07/14)
A study suggests that the risk of getting mesothelioma due to the exposure is not lower, even if you don’t work in construction. Read More.

Systematic Review of the Effects of Asbestos Exposure on the Risk of Cancer Between Children and Adults
(NCBI, 01/30/14)
The study conducted to investigate whether the first asbestos exposure in childhood increases the risk of asbestos-related cancer including mesothelioma and lung cancer.  Read More.

Mesothelioma Battle for Family
(Stuff, 01/27/14)
Facts and numbers for family mesothelioma battles. Read More.

Geologists discover naturally occurring asbestos fibers in Southern Nevada

(Las Vegas Review-Journal, 12/25/13)
The same type of naturally occurring asbestos-like fiber found in Mexico and Turkey has recently been discovered in Southern Nevada. Read More.

Study Says Mexican Mesothelioma Risk May Rival that of Turkey, According to Surviving Mesothelioma
(PR Web, 12/06/13)
A natural mineral called “Erionite” which has a similar structure to asbestos and can cause MPM. It is found in large amounts in Mexico and Turkey which has lead to increase in mesothelioma deaths in those countries. Read More.

Asbestos is Still With Us: Repeat Call for a Universal Ban
(New Solutions: a journal of environmental and occupational health policy, 2010)
All forms of asbestos are proven human carcinogens and there is no safe threshold of exposure. Asbestos is now banned in 52 countries and safer products have replaced many materials that once were made with asbestos. Nonetheless, a large number of countries still use, import, and export asbestos and asbestos-containing products. Countries of the world must once again join in the international endeavor to ban all forms of asbestos. Read More.

Malignant Mesothelioma Among Employees of a Connecticut Factory that Manufactured Friction Materials Using Chrysotile
(The Annals of Occupational Hygiene06/10/13)
There is ongoing argument about the potency of chrysotile asbestos to cause malignant mesothelioma. Study discusses the Raybestos Manhattan friction products plant in Connecticut, a plant that essentially used only chrysotile asbestos in relation to the most recent epidemiological information for chrysotile. Calculation suggests that mesothelioma rates at this plant were similar to those observed among Quebec miners and the South Carolina textile plant. We urge everyone concerned with the risk assessment of chrysotile asbestos to make use of all available data. Read More.

Porcelain Factory Worker With Asbestos-related Mesothelioma
(Journal of the Formosan Medical Association05/10/13)
Asbestos is a significant source of hazardous exposure in old buildings, and this case serves as a reminder of the importance of asbestos-related exposure history, which facilitated the correct diagnosis of pulmonary malignant mesothelioma. Asbestos-containing materials that are now banned or regulated are still present in older buildings and remain an exposure hazard; they continue to be a serious health concern in many countries. Read More.

Back to top